Drugs & Pharmaceuticals M&A » By The Online Investor Staff, updated Fri., Feb. 3, 11:43 AM
Recent mergers and acquisitions in the Drugs & Pharmaceuticals M&A category.
| This Slide: #23 of 100 |
Slide #23. Mallinckrodt plc — Cadence Pharmaceuticals, Inc.
Acquirer:
Mallinckrodt plc (MNK)
Acquiree:
Cadence Pharmaceuticals, Inc. (CADX)
Details:
Mallinckrodt plc (NYSE:MNK), a leading global specialty pharmaceuticals company, today announced the successful completion of its acquisition of Cadence Pharmaceuticals, Inc. (NASDAQ:CADX) for total consideration of approximately $1.4 billion. As previously disclosed, Mallinckrodt expects that the acquisition will be immediately accretive to its fiscal year 2014 adjusted diluted earnings per share, and significantly accretive to its fiscal year 2015 adjusted diluted earnings per share.
Mallinckrodt develops, manufactures, and markets pharmaceutical products and diagnostic imaging agents. Co. focuses on the manufacturing of pain management medications. Co provides its products to several wholesalers and retail drug store chains.
Open the MNK Page at The Online Investor »
Mallinckrodt develops, manufactures, and markets pharmaceutical products and diagnostic imaging agents. Co. focuses on the manufacturing of pain management medications. Co provides its products to several wholesalers and retail drug store chains.
Open the CADX Page at The Online Investor »
|
|||||||||||||||
|
|||||||||
 Free Email Alerts:
Get SEC Filing Alerts Get Dividend Alerts 
|
